Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality
JAMA · 07.05.2024 · 331 (17) · 1460
DOI: 10.1001/jama.2024.4011 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA, erschienen am 07.05.2024. Verfasst von Richard M Martin und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom. Hauptthemen laut MEDLINE: Early Detection of Cancer, Prostate-Specific Antigen, Prostatic Neoplasms. Die Arbeit wurde bisher 121-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Cancer Research UK, Medical Research Council, Department of Health.
Abstract (Originalsprache)
Importance The Cluster Randomized Trial of PSA Testing for Prostate Cancer (CAP) reported no effect of prostate-specific antigen (PSA) screening on prostate cancer mortality at a median 10-year follow-up (primary outcome), but the long-term effects of PSA screening on prostate cancer mortality remain unclear.
Objective
To evaluate the effect of a single invitation for PSA screening on prostate cancer–specific mortality at a median 15-year follow-up compared with no invitation for screening. Design, Setting, and Participants This secondary analysis of the CAP randomized clinical trial included men aged 50 to 69 years identified at 573 primary care practices in England and Wales. Primary care practices were randomized between September 25, 2001, and August 24, 2007, and men were enrolled between January 8, 2002, and January 20, 2009. Follow-up was completed on March 31, 2021.
Intervention
Men received a single invitation for a PSA screening test with subsequent diagnostic tests if the PSA level was 3.0 ng/mL or higher. The control group received standard practice (no invitation). Main Outcomes and Measures The primary outcome was reported previously. Of 8 prespecified secondary outcomes, results of 4 were reported previously. The 4 remaining prespecified secondary outcomes at 15-year follow-up were prostate cancer–specific mortality, all-cause mortality, and prostate cancer stage and Gleason grade at diagnosis.
Results
Of 415 357 eligible men (mean [SD] age, 59.0 [5.6] years), 98% were included in these analyses. Overall, 12 013 and 12 958 men with a prostate cancer diagnosis were in the intervention and control groups, respectively (15-year cumulative risk, 7.08% [95% CI, 6.95%-7.21%] and 6.94% [95% CI, 6.82%-7.06%], respectively). At a median 15-year follow-up, 1199 men in the intervention group (0.69% [95% CI, 0.65%-0.73%]) and 1451 men in the control group (0.78% [95% CI, 0.73%-0.82%]) died of prostate cancer (rate ratio [RR], 0.92 [95% CI, 0.85-0.99]; P = .03). Compared with the control, the PSA screening intervention increased detection of low-grade (Gleason score [GS] ≤6: 2.2% vs 1.6%; P < .001) and localized (T1/T2: 3.6% vs 3.1%; P < .001) disease but not intermediate (GS of 7), high-grade (GS ≥8), locally advanced (T3), or distally advanced (T4/N1/M1) tumors. There were 45 084 all-cause deaths in the intervention group (23.2% [95% CI, 23.0%-23.4%]) and 50 336 deaths in the control group (23.3% [95% CI, 23.1%-23.5%]) (RR, 0.97 [95% CI, 0.94-1.01]; P = .11). Eight of the prostate cancer deaths in the intervention group (0.7%) and 7 deaths in the control group (0.5%) were related to a diagnostic biopsy or prostate cancer treatment. Conclusions and Relevance In this secondary analysis of a randomized clinical trial, a single invitation for PSA screening compared with standard practice without routine screening reduced prostate cancer deaths at a median follow-up of 15 years. However, the absolute reduction in deaths was small. Trial Registration isrctn.org Identifier: ISRCTN92187251
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
- National Institute for Health Research Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, United Kingdom.
- MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom.
- Health Data Research UK South-West, University of Bristol, Bristol, United Kingdom.
- Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom.
- Department of Applied Health Research, University College London, London, United Kingdom.
Förderung
- Cancer Research UK
- Medical Research Council
- Department of Health
Zitieren
APA
Martin, R. M., Turner, E. L., Young, G. J., Metcalfe, C., Walsh, E. I., Lane, J. A., Sterne, J. A. C., Noble, S., Holding, P., Ben-Shlomo, Y., Williams, N. J., Pashayan, N., Bui, M. N., Albertsen, P. C., Seibert, T. M., Zietman, A. L., Oxley, J., Adolfsson, J., Mason, M. D., …, & CAP Trial Group (2024). Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality. JAMA, 331(17), 1460. https://doi.org/10.1001/jama.2024.4011
Vancouver
Martin RM, Turner EL, Young GJ, Metcalfe C, Walsh EI, Lane JA, et al. Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality. JAMA. 2024;331(17):1460. doi:10.1001/jama.2024.4011
BibTeX
@article{Martin2024,
author = {Martin, Richard M and Turner, Emma L and Young, Grace J and Metcalfe, Chris and Walsh, Eleanor I and Lane, J Athene and Sterne, Jonathan A C and Noble, Sian and Holding, Peter and Ben-Shlomo, Yoav and Williams, Naomi J and Pashayan, Nora and Bui, Mai Ngoc and Albertsen, Peter C and Seibert, Tyler M and Zietman, Anthony L and Oxley, Jon and Adolfsson, Jan and Mason, Malcolm D and Davey Smith, George and Neal, David E and Hamdy, Freddie C and Donovan, Jenny L and CAP Trial Group, CAP Trial Group},
title = {Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality},
journal = {JAMA},
year = {2024},
volume = {331},
number = {17},
pages = {1460},
doi = {10.1001/jama.2024.4011}
}
EUVIMED